Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29224598 | 0.82 | CHRM2 (0.36) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL25248672 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL22092594 | 0.80 | CYP1A2 (0.39) | ALDH1A1KMT2AMAPTGAA | |
| SCHEMBL11004912 | 0.80 | CYP1A2 (0.39) | ALDH1A1KMT2AMAPTGAA | |
| SCHEMBL29329219 | 0.80 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL29328751 | 0.80 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL16925552 | 0.79 | KMT2A (0.41) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL29328698 | 0.77 | ALDH1A1 (0.38) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL855129 | 0.77 | ALDH1A1 (0.45) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL15416050 | 0.77 | TLR4 (0.45) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104591989-B | The preparation method of 5 [(4 chlorphenyl) methyl] 2,2 cyclopentanone dimethyls | 上海华谊（集团）公司 | 2017-08-29 | — | — | CN | claimed |
| CN-118027058-A | 15-PGDH inhibitors | 武汉人福创新药物研发中心有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-9499519-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499519-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9422267-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422267-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2015028848-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS MULTI-KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2015-03-05 | — | — | WO | disclosed |
| WO-2014105958-A2 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | IGF1R, FGFR3, FGFR1 | ALDH1A1 3567/4885KDM4E 3165/4885MEN1 2958/4885 |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | IGF1R, IPMK, IP6K2 | ALDH1A1 3068/4885KDM4E 2755/4885MEN1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.